Sunitin 12.5 Capsule contains Sunitinib 12.5 mg, a targeted anticancer medicine used in the management of specific advanced and metastatic cancers. It helps control cancer progression by blocking certain proteins and signaling pathways responsible for tumor growth and the formation of new blood vessels that support cancer cells. The capsule is prescribed under the supervision of oncology specialists and is used as part of personalized cancer treatment approaches.

Sunitinib belongs to the multikinase inhibitor class and works by inhibiting receptor tyrosine kinases involved in angiogenesis, tumor cell proliferation, and cancer cell survival. By interfering with these important biological pathways, it helps reduce the supply of nutrients to tumors and slows the growth and spread of malignant cells. Its targeted mechanism makes it a valuable option in modern oncology therapy.

The capsule is commonly prescribed for renal cell carcinoma, gastrointestinal stromal tumors (GIST), pancreatic neuroendocrine tumors, and other malignancies as determined by an oncology specialist. It may be used as a single therapy or incorporated into a broader treatment plan based on disease progression and patient response. Regular medical monitoring is important during therapy to evaluate effectiveness and manage possible treatment-related effects.

With the increasing adoption of targeted cancer treatments and growing demand for advanced oncology medicines, Sunitin 12.5 Capsule maintains strong relevance in the anticancer segment. Its established therapeutic role, broad clinical applications, and acceptance among healthcare professionals contribute to consistent market demand. The product offers valuable business opportunities and sustainable growth potential for retailers and distributors operating within the oncology pharmaceutical sector.

Sunitin 12.5 Capsule may cause fatigue, nausea, vomiting, diarrhea, decreased appetite, abdominal discomfort, mouth ulcers, skin changes, hand-foot syndrome, and increased blood pressure. Serious adverse effects such as liver dysfunction, cardiac complications, bleeding events, thyroid abnormalities, and kidney function changes may occur and require close medical supervision.

Sunitin 12.5 Capsule is indicated for the treatment of renal cell carcinoma, gastrointestinal stromal tumors (GIST), pancreatic neuroendocrine tumors, and other cancers as determined by an oncology specialist. It helps inhibit tumor growth, reduce angiogenesis, and support comprehensive cancer management.

This medication should be used only under the supervision of a qualified healthcare professional experienced in oncology treatment. Regular monitoring of blood pressure, liver function, kidney function, thyroid function, blood counts, and overall patient health is essential throughout therapy. Patients should promptly report unusual bleeding, chest discomfort, severe fatigue, breathing difficulties, or any other concerning symptoms. Treatment should always be individualized according to the patient's condition and response to therapy.

Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the capsules in their original packaging and out of reach of children. Do not use after the expiry date or if the packaging is damaged, opened, or shows signs of tampering.